FrancophonIA/ELRC3.0 huggingface dataset:
English: Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxicmedicinal products.
Danish: Dehydrering kan forårsage akut nyreinsufficiens særligt hos patienter med eksisterende kompromitteret nyrefunktion, eller når capecitabin gives samtidigt med lægemidler med kendt nefrotoksisk effekt.
English: LIST OF EXCIPIENTS Also contains anhydrous lactose See package leaflet for further information.
Danish: LISTE OVER HJÆLPESTOFFER Indeholder også vandfri lactose.Se indlægssedlen for yderligere information.
English: If you stop taking Xeloda
Danish: Hvis du holder op med at tage Xeloda
English: Dose changes within a treatment cycle
Danish: Dosisændringer under en behandlingsserie
English: Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline).
Danish: Capecitabin er kontraindiceret til patienter med svær nedsat nyrefunktion (creatininclearance under 30 ml/min ved baseline) [Cockcroft og Gault].
English: Table 7 Key efficacy results for the non-inferiority analysis of Study NO16966
Danish: Tabel 7 Nøgleresultaterne for effekt af non-inferioritetsanalysen af studie NO16966
English: If no toxicity is observed in patients ≥60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Danish: Hvis der ikke ses toksicitet hos patienter ³ 60 år, som behandles med en nedsat initialdosis af capecitabin i kombination med docetaxel, kan capecitabin-dosis med forsigtighed øges til 1.250 mg/m2 to gange dagligt.
English: Hazard ratio 95% CI
Danish: Hazard ratio 95 % konfidensinterval p-værdi
English: Elderly: Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Danish: Baseret på populationsfarmakokinetiske analyser, som omfattede patienter i mange aldre (27 - 86 år), og som omfattede 234 (46 %) patienter, som var mindst 65 år, spillede alderen ingen rolle for farmakokinetikken af 5'-DFUR og 5-FU.
English: Capecitabine Monotherapy:
Danish: Capecitabin-monoterapi:
English: Table 9 Key efficacy results for the non-inferiority analysis of Study NO16967
Danish: Tabel 9 Nøgleresultater fra non-inferioritetsanalyserne af studie NO16967
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Danish: Du kan finde yderligere oplysninger om Xeloda på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
English: Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Danish: Der blev set kardiovaskulær toksicitet (f.eks. forlængelse af PR- og QT-intervallet) hos cynomolgusabe efter intravenøs administration (100 mg/kg), men ikke efter gentagen oral dosering (1.379 mg/m2/dag)
English: If you cannot swallow Xeloda tablets whole, tell your healthcare provider.
Danish: Hvis du ikke kan sluge Xeloda tabletterne hele, skal du kontakte din læge eller sygeplejerske.
English: Breast cancer:
Danish: Brystkræft:
English: Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel or paclitaxel (Cmax and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5'DFUR.
Danish: Fase I-studier, som evaluerede capecitabins effekt på enten docetaxels eller paclitaxels farmakokinetik og vice versa, viste ingen effekt af capecitabin på hverken docetaxels eller paclitaxels farmakokinetik (Cmax og AUC) og inden effekt af docetaxel eller paclitaxel på 5'-DFUR's farmakokinetik.
English: There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Xeloda.
Danish: Der er nogen evidens for, at dexpanthenol er virksomt som profylakse mod hånd- og fodsyndrom hos patienter, der behandles med Xeloda.
English: If you have an unrecognised DPD deficiency and take Xeloda, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Danish: Hvis du har DPD-mangel uden at vide det og tager Xeloda, har du en øget risiko for akut tidlig indtræden af bivirkningerne, anført i punkt 4 Bivirkninger, i svær form.
English: Petechiae,
Danish: Pyreksi,
English: If you forget to take Xeloda
Danish: Hvis du har glemt at tage Xeloda
English: In the absence of safety and efficacy data in patients with hepatic impairment, Capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
Danish: Da der ikke findes sikkerheds- og effektdata hos patienter med leverinsufficiens skal anvendelsen af capecitabin kontrolleres omhyggeligt hos patienter med let til moderat leverdysfunktion, uanset om der er levermetastaser eller ej.
English: • Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
Danish: · Stevens-Johnsons syndrom: hvis du oplever smertefuldt rødt eller lilla udslæt, der spreder sig og danner blistre og/eller andre læsioner, der opstår i slimhinderne (fx mund eller læber), især hvis du tidligere har været følsom over for lys, haft infektioner i luftvejene (fx bronkitis) og/eller feber.
English: In case of exposure of either patient or caregiver to crushed or cut Xeloda tablets adverse drug reactions could occur (see Section 4.8).
Danish: I tilfælde, hvor enten patienten eller patientens omsorgsperson udsættes for delte eller knuste Xeloda tabletter, kan der opstå bivirkninger (se pkt 4.8).
English: If you are a woman who could become pregnant you should use effective contraception during treatment with XELODA and for 6 months after the last dose.
Danish: Hvis du er en kvinde, der kan blive gravid, skal du anvende sikker prævention under behandling med Xeloda og i 6 måneder efter sidste dosis.
English: The European Medicines Agency has waived the obligation to conduct studies with Xeloda in all subsets of the paediatric population in adenocarcinoma of the colon and rectum, gastric adenocarcinoma and breast carcinoma (see section 4.2 for information on paediatric use).
Danish: Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at udføre studier med Xeloda i alle undergrupper af den pædiatriske population med adenokarcinom i colon og rektum, ventrikeladenokarcinom og brystkarcinom (se pkt.
English: Cutaneous lupus erythematosus (rare), Severe skin reactions such as StevensJohnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4.)
Danish: Kutan lupus erythematosus (sjælden), Alvorlige hudreaktioner såsom StevensJohnsons syndrom og toksisk epidermal nekrolyse (meget sjælden) (se pkt.
English: Also, you need to be particularly careful if you are taking any of the following: gout medicines (allopurinol), blood-thinning medicines (coumarin, warfarin), medicines for seizures or tremors (phenytoin), interferon alpha, radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, cisplatin, irinotecan),
Danish: Du skal også være særlig forsigtig, hvis du tager: · medicin mod urinsyregigt (allopurinol), · blodfortyndende medicin (coumarin eller warfarin), · medicin mod kramper eller rystelser (phenytoin), · alfa-interferon, · får strålebehandling og bestemte lægemidler mod kræft (folinsyre, oxaliplatin, bevacizumab,
English: Periodic Safety Update Reports
Danish: · Periodiske, opdaterede sikkerhedsindberetninger (PSUR'er)
English: If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with XELODA and for 3 months after the last dose.
Danish: Hvis du er en mandlig patient og din kvindelige partner kan blive gravid, så skal du anvende sikker prævention under behandling med Xeloda og i 3 måneder efter sidste dosis.
English: In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus ≥1).
Danish: I alle studierne kombineret var følgende kovarianter statistisk signifikant associeret med en øget risiko for udviklingen af hånd- og fodsyndrom: stigende capecitabin-startdosis (gram), faldende kumulativ capecitabin-dosis (0,1 *kg), stigende relativ dosisintensitet i de første seks uger, længere behandlingsvarighed (uger), stigende alder (ved 10-års forøgelse), kvindeligt køn og med en god ECOG performancestatus ved baseline (0 versus ≥1).
English: - metastatic colorectal cancer (see section 5.1).
Danish: -metastatisk kolorektalkræft (se pkt.
English: Treatment with capecitabine monotherapy may be resumed when bilirubin decreases to ≤3.0 x ULN or hepatic aminotransferases decrease to ≤ 2.5 x ULN.
Danish: Behandlingen med capecitabin-monoterapi kan genoptages, når bilirubin er faldet til ≤ 3,0 x UNL eller levertransaminaserne er faldet til £ 2,5 x UNL.
English: Other medicines and Xeloda
Danish: Brug af anden medicin sammen med Xeloda
English: An analysis of safety data in patients ≥60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients <60 years of age.
Danish: En analyse af sikkerhedsdata fra patienter ³ 60 år, som behandledes med capecitabin-monoterapi og en analyse af patienter, som behandledes med capecitabin plus docetaxel, viste en stigning i incidensen af behandlingsrelaterede bivirkninger af grad 3 og 4 og af behandlingsrelaterede alvorlige bivirkninger, sammenlignet med patienter < 60 år.
English: Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus (e.g. DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of lifethreatening or fatal toxicity and should not be treated with Xeloda (see section 4.3).
Danish: Selvom DPD-mangel ikke kan fastsættes præcist, er det kendt, at patienter med visse homozygote eller visse sammensatte heterozygote mutationer i DPYD-genlocuset (fx DPYD*2A, c.1679T>G, c.2846A>T og c.1236G>A/HapB3 varianter), som kan forårsage fuldstændigt eller næsten fuldstændigt fravær af DPD-enzymaktivitet (bestemt ved laboratorieprøver), har den højeste risiko for livstruende eller dødelig toksicitet, og disse patienter bør ikke behandles med Xeloda (se pkt.
English: However, folinic acid has an effect on the pharmacodynamics of capecitabine and its toxicity may be enhanced by folinic acid: the maximum tolerated dose (MTD) of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day whereas it is only 2000 mg/m2 per day when capecitabine was combined with folinic acid (30 mg orally bid).
Danish: Folinsyre har imidlertid en effekt på capecitabins farmakodynamik og dets toksicitet kan blive forstærket af folinsyre: maksimum tolererbar dosis (MTD) af capecitabin efter behandling med capecitabin alene er ved intermitterende behandling 3.000 mg/m pr. dag, hvorimod den kun er 2.000 mg/m pr. dag, når capecitabin kombineres med folinsyre (30 mg oralt to gange dagligt).
English: Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Danish: Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin, eller har gjort det for nylig.
English: Xeloda should only be prescribed by a doctor experienced in the use of anticancer medicines.
Danish: Xeloda må kun ordineres af læger med erfaring i brug af kræftmedicin.
English: • DPD Deficiency: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).
Danish: · DPD-mangel: hvis du ved, at du har DPD-mangel, har du en øget risiko for akut tidlig indtræden af bivirkninger og svære, livstruende eller dødelige bivirkninger forårsaget af XELODA (f.eks. mundbetændelse, betændelseslignende reaktion (inflammation) i slimhinder, diarré, neutropeni og neurotoksicitet)
English: Patients with hepatic impairment due to liver metastases: According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Danish: Patienter med leverinsufficiens pga. levermetastaser I henhold til et farmakokinetisk studie på kræftpatienter med let til moderat leverinsufficiens pga. levermetastaser kan capecitabins biotilgængelighed og eksponeringen for 5-FU øges sammenlignet med patienter uden leverinsufficiens.
English: - as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Danish: -som monoterapi til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af taxaner og et kemoterapiregime indeholdende et antracyklin eller hos hvem antracyklinbehandling ikke er indiceret.
English: Table 4 Summary of related ADRs reported in patients treated with capecitabine monotherapy Body System Very Common
Danish: Tabel 4 Sammenfatning af relaterede bivirkninger, som blev rapporteret hos patienter behandlet med capecitabin-monoterapi Systemorganklasse
English: Very rare side effects (may affect up to 1 in 10,000 people) include: severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)
Danish: Meget sjældne bivirkninger (kan påvirke op til 1 ud af 10.000 personer): · svære hudreaktioner såsom hududslæt, sårdannelse og blæredannelse, som kan give sår i munden, næsen, kønsorganer, hænder, fødder og øjne (røde og opsvulmede øjne).
English: INFORMATION IN BRAILLE xeloda 150 mg
Danish: INFORMATION I BRAILLESKRIFT Xeloda 150 mg
English: You might get the following side effects if you take a lot more capecitabine than you should: feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells).
Danish: Du kan få følgende bivirkninger, hvis du kommer til at tage meget mere capecitabin, end du skulle: kvalme, diarré, irritation eller sårdannelse i tarmen eller munden, smerter og blødning fra tarmene eller maven eller påvirkning af knoglemarven (nedsat antal bestemte former for blodlegemer).
English: Bone marrow depression, +Febrile Neutropenia
Danish: Knoglemarvsdepressio n, +Febril neutropeni
English: Patients ≥60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients <60 years of age.
Danish: Der var flere patienter ³ 60 år, som behandledes med capecitabin plus docetaxel, som måtte stoppe behandlingen tidligt på grund af bivirkninger, sammenlignet med patienter < 60 år.
English: • Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
Danish: · Mundbetændelse: hvis du har smerter, rødme, hævelse eller sår i din mund og/eller hals.
English: Xeloda contains anhydrous lactose
Danish: Xeloda indeholder lactose, vandfri
English: Table 5 Summary of related ADRs reported in patients treated with capecitabine in combination treatment in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy Body System
Danish: Tabel 5 Sammenfatning af relaterede bivirkninger, som blev rapporteret hos patienter, der blev behandlet med capecitabin i kombinationsbehandling set ud over bivirkninger efter behandling med capecitabin-monoterapi eller set i en højere frekvensgruppe sammenlignet med capecitabin-monoterapi
English: In patients with moderate renal impairment at baseline, no dose reduction is required for a starting dose of 1000 mg/m2.
Danish: Til patienter med moderat nedsat nyrefunktion ved baseline er det for en initialdosis på 1.000 mg/m2 ikke nødvendigt med dosisjustering.
English: INFORMATION IN BRAILLE xeloda 500 mg
Danish: INFORMATION I BRAILLESKRIFT Xeloda 500 mg
English: Elderly patients (see section 4.2):
Danish: Ældre patienter (se pkt.
English: The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV.
Danish: Raten for 3 års sygdomsfri overlevelse var 71 % for XELOX versus 67 % for 5-FU/LV.
English: Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described.
Danish: Der er beskrevet en klinisk signifikant interaktion mellem brivudin og fluorpyrimidiner (f.eks. capecitabin, 5-FU, tegafur), som et resultat af brivudins hæmning af dihydropyrimidindehydrogenase.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Danish: DATO FOR ÆNDRING AF TEKSTEN Yderligere oplysninger om Xeloda findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
English: Severe skin reactions: Xeloda can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Danish: Xeloda kan inducere alvorlige hudreaktioner såsom Stevens-Johnsons syndrom og toksisk epidermal nekrolyse.
English: In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.
Danish: Til patienter med let nedsat nyrefunktion (creatininclearance 5180 ml/min ved baseline) er dosisjustering ikke nødvendig.
English: Capecitabine in combination therapy:
Danish: Capecitabin i kombinationsbehandling
English: What you need to know before you take Xeloda
Danish: Det skal du vide, før du begynder at tage Xeloda
English: Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily.
Danish: Her følger to eksempler: En person, som vejer 64 kg, og som er 1,64 m høj, har et legemsoverfladeareal på 1,7 m2 og skal tage 4 tabletter á
English: MARKETING AUTHORISATION NUMBER(S) EU/1/00/163/001
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/00/163/001
English: Do not take Xeloda:
Danish: Xeloda indeholder:
English: At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
Danish: Efter en dosis på 1250 mg/m2 efter indtagelse af føde var peak-plasmakoncentrationerne på dag 14 (Cmax, mg/ml) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL 4,67; 3,05; 12,1; 0,95 og 5,46.
English: In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
Danish: Hvis du bruger blodfortyndende medicin (antikoagulantia) af coumarintypen (indeholdende f.eks. phenprocoumon) kan det blive nødvendigt, at din læge ændrer dosis af denne medicin, hvis behandlingen med capecitabin stopper.
English: Patients with renal impairment: Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU.
Danish: Baseret på et farmakokinetisk studie hos kræftpatienter med let til svær nyreinsufficiens er der ingen tegn på effekt af creatininclearance på farmakokinetikken af det intakte lægemiddel og 5-FU.
English: 604 patients were randomised to treatment with 5-FU and leucovorin (Mayo regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days).
Danish: 604 patienter randomiseredes til behandling med 5-FU og leucovirin (Mayo regime: 20 mg/m2 leucovirin intravenøs efterfulgt af en 5-FU bolus på 425 mg/m2 intravenøs på dag 1 til 5, hver 28.
English: Interferon alpha: the MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha-2a (3 MIU/m2 per day) compared to 3000 mg/m2 per day when capecitabine was used alone.
Danish: Capecitabins MTD var 2.000 mg/m2/dag, når det kombineredes med interferon alfa-2a (3 MIE/m2/dag) sammenlignet med 3.000 mg/m2/dag, når capecitabin blev givet alene.
English: Xeloda may make you feel dizzy, nauseous or tired.
Danish: Xeloda kan forårsage svimmelhed, kvalme og træthed.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/00/163/002
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/00/163/002
English: Posology adjustments during treatment
Danish: Dosisjustering under behandlingen
English: Standard and reduced dose calculations according to body surface area for starting doses of Xeloda of 1250 mg/m2 and 1000 mg/m2 are provided in tables 1 and 2, respectively.
Danish: Standard og reducerede initialdosisberegninger af Xeloda på 1.250 mg/m2 og 1.000 mg/m2 ud fra legemsoverfladeareal er anført i henholdsvis tabel 1 og 2.
English: Each pack contains 120 film-coated tablets (12 blisters of 10 tablets).
Danish: Hver pakning indeholder 120 filmovertrukne tabletter (12 blisterkort à 10 tabletter)
English: Each pack contains 60 film-coated tablets (6 blisters of 10 tablets).
Danish: Hver pakning indeholder 60 filmovertrukne tabletter (6 blisterkort à 10 tabletter)
English: The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64 - 1.13).
Danish: Resultatet for hazard ratio for varighed af overlevelse (samlet overlevelse) svarede til resultatet for hazard ratio for progressionsfri overlevelse (hazard ratio 0,85, 95 % konfidensinterval 0,64 - 1,13).
English: Xeloda is used in the treatment of colon, rectal, gastric, or breast cancers.
Danish: Xeloda bruges til behandling af kræft i tyktarm, endetarm, mave eller bryst.
English: Leucovorin 200 mg/m intravenous 2 hr
Danish: Leucovorin 200 mg/m2 intravenøs 2 timer
English: Parameter: Overall Survival PPP
Danish: Parameter: Samlet overlevelse PPP
English: Vascular disorders Lower limb oedema, Hypertension, +Embolism and thrombosis
Danish: Vaskulære sygdomme Ødem i underekstremiteter, Hypertension, +Embolisme og tromboser
English: Parameter: Overall Survival EPP
Danish: Parameter: Samlet overlevelse EPP
English: PHARMACEUTICAL FORM AND CONTENTS 60 film-coated tablets
Danish: LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 60 filmovertrukne tabletter
English: Key efficacy results for AIO KRK study XELOX + bevacizumab
Danish: Tabel 8: Nøgleresultater for effekt fra AIO KRK-studiet XELOX + bevacizumab